AU2002224022A1 - Preventives or remedies for endoplasmic reticulum stress-associated diseases - Google Patents

Preventives or remedies for endoplasmic reticulum stress-associated diseases

Info

Publication number
AU2002224022A1
AU2002224022A1 AU2002224022A AU2402202A AU2002224022A1 AU 2002224022 A1 AU2002224022 A1 AU 2002224022A1 AU 2002224022 A AU2002224022 A AU 2002224022A AU 2402202 A AU2402202 A AU 2402202A AU 2002224022 A1 AU2002224022 A1 AU 2002224022A1
Authority
AU
Australia
Prior art keywords
preventives
remedies
endoplasmic reticulum
associated diseases
reticulum stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224022A
Inventor
Hidenori Ichijyo
Atsushi Matsuzawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of AU2002224022A1 publication Critical patent/AU2002224022A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
AU2002224022A 2000-11-10 2001-11-08 Preventives or remedies for endoplasmic reticulum stress-associated diseases Abandoned AU2002224022A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000344516 2000-11-10
JP2000-344516 2000-11-10
PCT/JP2001/009792 WO2002038179A1 (en) 2000-11-10 2001-11-08 Preventives or remedies for endoplasmic reticulum stress-associated diseases

Publications (1)

Publication Number Publication Date
AU2002224022A1 true AU2002224022A1 (en) 2002-05-21

Family

ID=18818701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224022A Abandoned AU2002224022A1 (en) 2000-11-10 2001-11-08 Preventives or remedies for endoplasmic reticulum stress-associated diseases

Country Status (3)

Country Link
JP (1) JPWO2002038179A1 (en)
AU (1) AU2002224022A1 (en)
WO (1) WO2002038179A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063905A1 (en) * 2002-01-31 2003-08-07 Center For Advanced Science And Technology Incubation, Ltd. Preventives or remedies for immunological diseases
JP4925155B2 (en) * 2002-06-10 2012-04-25 レドックス・バイオサイエンス株式会社 Retinal nerve cell function recovery agent
WO2004048565A1 (en) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Apoptosis-associated protein and use thereof
JP4488720B2 (en) * 2002-11-22 2010-06-23 武田薬品工業株式会社 Apoptosis-related proteins and uses thereof
EP1661581A1 (en) * 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
WO2005103288A1 (en) 2004-04-27 2005-11-03 Takeda Pharmaceutical Company Limited Screening method
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical Fused heterocyclic compound
EP2268821A1 (en) * 2008-04-25 2011-01-05 New York Blood Center, Inc. Abi1/hssh3bp1 conditional knockout mouse
TWI625121B (en) * 2009-07-13 2018-06-01 基利科學股份有限公司 Apoptosis signal-regulating kinase inhibitors
ES2842749T3 (en) 2014-12-23 2021-07-14 Gilead Sciences Inc Processes for preparing ASK1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3839103B2 (en) * 1996-04-19 2006-11-01 財団法人癌研究会 Apoptosis-inducing protein and gene encoding the same
KR100399982B1 (en) * 2000-06-16 2003-11-13 학교법인고려중앙학원 Novel mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting with ASK1 and use thereof

Also Published As

Publication number Publication date
WO2002038179A1 (en) 2002-05-16
JPWO2002038179A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2002313236A1 (en) Medicinal compositions
AU2001246876A1 (en) Remedies
AU2001253265A1 (en) Oral treatment systems
AU2001246877A1 (en) Remedies
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2002242883A1 (en) Medicament dispenser
AU2001286221A1 (en) Remedies for ischemic diseases
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU2002258221A1 (en) Medicinal composition
AU2002214324A1 (en) Medicinal compositions
AU2000279614A1 (en) Remedies for endothelin-induced diseases
AU2002224022A1 (en) Preventives or remedies for endoplasmic reticulum stress-associated diseases
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU1732401A (en) Medicinal compositions for oral use
AU2001236006A1 (en) Preventives/remedies for kidney diseases
AU2001241162A1 (en) Remedies for allergic diseases
AU2002315848A1 (en) Remedies for eosinophilic diseases
AU2001271026A1 (en) Remedies for bone diseases
AU2002354460A1 (en) Medicinal composition
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2003266605A1 (en) Preventives/remedies for neurodegenerative disease
AU2001282541A1 (en) Medicinal compositions
AU2003275360A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions